Market Overview:
The global saxagliptin API market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of type 2 diabetes, increasing R&D investments for novel drugs, and growing demand for saxagliptin tablets. However, patent expiries of key marketed drugs may restrain the growth of the market during the forecast period. Based on type, the global saxagliptin API market is segmented into purity greater than or equal to 98% and purity greater than or equal to 99%. The purity greater than or equal to 98% segment is expected to account for a larger share of the global saxagliptin API market in 2018. This can be attributedto higher adoption ratesof products with high purities by pharmaceutical companies and research institutes. Based on application,theglobal saxagliptin APImarket is segmented into Saxagliptin Tabletsand Other applications.
Product Definition:
Saxagliptin is a medication used to treat type 2 diabetes. It is used along with diet and exercise to improve blood sugar control in adults who do not have enough of the hormone insulin. Saxagliptin also helps to prevent episodes of low blood sugar (hypoglycemia).
PurityGreater than or equal to98%:
Purity Greater than or equal to 98% is a new type of monoclonal antibody, which has been developed by AbbVie Inc. It's an insulin-degrading enzyme inhibitor that works by decreasing the activity of amyloidosis in patients with pancreatic cancer. The drug’s mechanism of action differs from that of traditional anti-cancer drugs as it specifically targets the abnormal protein responsible for causing tumor growth rather than just treating the symptoms.
PurityGreater than or equal to99%:
Purity Greater than or equal to 99% is a special type of purity which means that the final product should contain more than 99% of the active ingredient. It is also known as Pharmaceutical Grade or PGM99%. The main reason for using such high grade products in pharmaceuticals industry is because it ensures that there will be no loss of active ingredients during process and also provides better quality end-product.
Application Insights:
Saxagliptin tablets were the most prominent application of the drug and accounted for a revenue share of over 55% in 2017. The product is used to treat patients with diabetes mellitus type II who have been unresponsive to other oral hypoglycemic agents. It works by decreasing the liver's production of glucose thereby lowering blood sugar levels in the body.
The other segment that includes insulins, insulin analogs & NPH insulin are projected to witness significant growth over the forecast period owing to their rising usage rates as compared to regular insulin among patients suffering from diabetes mellitus type I and diabetic ketoacidosis. Increasing awareness about these drugs amongst healthcare professionals has also contributed significantly towards segment growth since 2014, when this information was first reported by WHO regarding various aspects related with these drugs (type I & II).
Regional Analysis:
North America dominated the global market in 2017. This is attributed to the high prevalence of diabetes and obesity, availability of effective treatment methods, well-established healthcare facilities, and government initiatives for controlling diabetes. Moreover, increasing R&D activities by various companies for developing novel drugs will drive growth over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising disposable income levels in emerging economies such as India & China and growing awareness about early diagnosis of diseases among people. Furthermore, a large population base suffering from diabetes is also expected to boost demand during this period due to lack of Saxagliptin API manufacturers in this region which has compelled them develop local manufacturing units thus driving regional market growth over the projected time frame.
Growth Factors:
- Increasing incidence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is primarily due to the changing lifestyle and dietary habits of people across the world. Saxagliptin, being a potent antidiabetic drug, is likely to find increased demand in the coming years.
- Growing awareness about diabetes and its treatment options: There has been a growing awareness about diabetes and its treatment options in recent years. This has led to an increase in the demand for antidiabetic drugs such as saxagliptin API worldwide.
- Rising incidence of obesity: Obesity is one of the major risk factors for developing type 2 diabetes mellitus (T2DM). As obesity rates continue to rise around the world, so will the number of people with T2DM, leading to an increase in demand for saxagliptin API products..
Scope Of The Report
Report Attributes
Report Details
Report Title
Saxagliptin API Market Research Report
By Type
PurityGreater than or equal to98%, PurityGreater than or equal to99%
By Application
Saxagliptin Tablets, Other
By Companies
AstraZeneca, Tapi Teva, API Polpharma, Metrochem API, Tianjin Scipharmacn, Taizhou Canova Bio-technology, Minxiang Pharma, Huaman Xincaiiao Keji, Jinan Lead Pharm-Chemical, Hebei Kangtai Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Saxagliptin API Market Report Segments:
The global Saxagliptin API market is segmented on the basis of:
Types
PurityGreater than or equal to98%, PurityGreater than or equal to99%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Saxagliptin Tablets, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Tapi Teva
- API Polpharma
- Metrochem API
- Tianjin Scipharmacn
- Taizhou Canova Bio-technology
- Minxiang Pharma
- Huaman Xincaiiao Keji
- Jinan Lead Pharm-Chemical
- Hebei Kangtai Pharma
Highlights of The Saxagliptin API Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- PurityGreater than or equal to98%
- PurityGreater than or equal to99%
- By Application:
- Saxagliptin Tablets
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Saxagliptin API Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Saxagliptin is an oral medication used to lower blood sugar in people with type 2 diabetes. Saxagliptin works by decreasing the amount of glucose produced by the liver.
Some of the major players in the saxagliptin api market are AstraZeneca, Tapi Teva, API Polpharma, Metrochem API, Tianjin Scipharmacn, Taizhou Canova Bio-technology, Minxiang Pharma, Huaman Xincaiiao Keji, Jinan Lead Pharm-Chemical, Hebei Kangtai Pharma.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Saxagliptin API Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Saxagliptin API Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Saxagliptin API Market - Supply Chain
4.5. Global Saxagliptin API Market Forecast
4.5.1. Saxagliptin API Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Saxagliptin API Market Size (000 Units) and Y-o-Y Growth
4.5.3. Saxagliptin API Market Absolute $ Opportunity
5. Global Saxagliptin API Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Saxagliptin API Market Size and Volume Forecast by Type
5.3.1. PurityGreater than or equal to98%
5.3.2. PurityGreater than or equal to99%
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Saxagliptin API Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Saxagliptin API Market Size and Volume Forecast by Application
6.3.1. Saxagliptin Tablets
6.3.2. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Saxagliptin API Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Saxagliptin API Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Saxagliptin API Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Saxagliptin API Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Saxagliptin API Demand Share Forecast, 2019-2026
9. North America Saxagliptin API Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Saxagliptin API Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Saxagliptin API Market Size and Volume Forecast by Application
9.4.1. Saxagliptin Tablets
9.4.2. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Saxagliptin API Market Size and Volume Forecast by Type
9.7.1. PurityGreater than or equal to98%
9.7.2. PurityGreater than or equal to99%
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Saxagliptin API Demand Share Forecast, 2019-2026
10. Latin America Saxagliptin API Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Saxagliptin API Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Saxagliptin API Market Size and Volume Forecast by Application
10.4.1. Saxagliptin Tablets
10.4.2. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Saxagliptin API Market Size and Volume Forecast by Type
10.7.1. PurityGreater than or equal to98%
10.7.2. PurityGreater than or equal to99%
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Saxagliptin API Demand Share Forecast, 2019-2026
11. Europe Saxagliptin API Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Saxagliptin API Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Saxagliptin API Market Size and Volume Forecast by Application
11.4.1. Saxagliptin Tablets
11.4.2. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Saxagliptin API Market Size and Volume Forecast by Type
11.7.1. PurityGreater than or equal to98%
11.7.2. PurityGreater than or equal to99%
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
1.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Saxagliptin API Demand Share, 2019-2026
12. Asia Pacific Saxagliptin API Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Saxagliptin API Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Saxagliptin API Market Size and Volume Forecast by Application
12.4.1. Saxagliptin Tablets
12.4.2. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Saxagliptin API Market Size and Volume Forecast by Type
12.7.1. PurityGreater than or equal to98%
12.7.2. PurityGreater than or equal to99%
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Saxagliptin API Demand Share, 2019-2026
13. Middle East & Africa Saxagliptin API Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Saxagliptin API Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Saxagliptin API Market Size and Volume Forecast by Application
13.4.1. Saxagliptin Tablets
13.4.2. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Saxagliptin API Market Size and Volume Forecast by Type
13.7.1. PurityGreater than or equal to98%
13.7.2. PurityGreater than or equal to99%
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Saxagliptin API Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Saxagliptin API Market: Market Share Analysis
14.2. Saxagliptin API Distributors and Customers
14.3. Saxagliptin API Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AstraZeneca
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Tapi Teva
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. API Polpharma
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Metrochem API
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Tianjin Scipharmacn
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Taizhou Canova Bio-technology
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Minxiang Pharma
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Huaman Xincaiiao Keji
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Jinan Lead Pharm-Chemical
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Hebei Kangtai Pharma
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
